Business Context and Reporting Period
This Form 8-K Current Report was filed by ReShape Lifesciences Inc. (trading symbol: RSLS) on June 16, 2022. The filing details a material definitive agreement entered into on the same date regarding the exercise of outstanding warrants by an existing accredited investor.
Key Financial Metrics and Transaction Details
- Gross Proceeds: Approximately $2.5 million from the warrant exercise.
- Shares Issued: 3.7 million shares of common stock issued upon exercise of existing warrants.
- New Warrants Issued: 3.7 million new unregistered warrants issued as consideration (100% of shares issued).
- Exercise Price Adjustment: The exercise price for the exercised warrants and 1.6 million remaining unexercised warrants was reduced from $6.00 to $0.6665 per share.
- Transaction Fees: Maxim Group LLC received a cash fee equal to 7.0% of gross proceeds.
- Use of Proceeds: Net proceeds are intended for commercial growth, working capital, and general corporate purposes.
Material Changes
The primary material change is the significant reduction in the warrant exercise price from $6.00 to $0.6665 per share, aligning it with the most recent closing price prior to the agreement. Additionally, the company's capital structure was altered by the issuance of 3.7 million new shares and an equivalent number of new warrants with a seven-and-a-half-year term.
Outlook, Risks, and Contingencies
- Registration Obligation: The Company agreed to file a resale registration statement on Form S-3 within 30 days for the new warrants and underlying shares.
- Ownership Limitation: The agreement includes a beneficial ownership limitation preventing the investor from owning more than 4.99% of the Company's outstanding common stock at any time.
- Regulatory Status: The new warrants were offered in a private placement under Section 4(a)(2) of the Securities Act and are not registered; they cannot be sold in the U.S. absent registration or an applicable exemption.
Investor Verification Checklist
- Verify the exact net proceeds after deducting the 7.0% agent fee and other offering expenses.
- Confirm the total number of outstanding warrants post-transaction (3.7 million new + 1.6 million remaining).
- Monitor the timely filing of the Form S-3 registration statement within the 30-day window.
- Review the impact of the 4.99% beneficial ownership limitation on future potential exercises by this investor.